Regulated expression of the interferon-β gene in mice

Gene Therapy

Volumn 15, Issue 1, 2008, Pages 1-11

  Harkins, R N ^a   Szymanski, P ^a   Petry, H ^a   Brooks, A ^a   Qian, H S ^a   Schaefer, C ^a   Kretschmer, P J ^a   Orme, A ^a   Wang, P ^a   Rubanyi, G M ^a   Hermiston, T W ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MESSENGER RNA; MIFEPRISTONE; PLASMID DNA; PLASMID VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE CONSTRUCT; GENE EXPRESSION REGULATION; GENE THERAPY; HINDLIMB; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; TRANSGENE;

ANIMALS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MICE; MICE, INBRED STRAINS; MIFEPRISTONE; MULTIPLE SCLEROSIS; PLASMIDS; PYRIMIDINONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLES; TRANSGENES;

MURINAE; MUS;

EID: 37349034391     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302998     Document Type: Article

References (38)

1. Compston A, oles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231.
2. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002; 53: 258-302.
3. Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85: 299-302.
4. Bayas A, Gold R. Lessons from 10 years of interferon beta-1b (Betaferon/ Betaseron) treatment. J Neurol 2003; 250 (Suppl 4): IV3-IV8.
5. Malucchi SM, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M et al. Neutralizing antibodies reduce the efficacy of IFNb during treatment of multiple sclerosis. Neurology 2004; 62: 2031-2037.
6. Triantaphyllopoulos K, Croxford J, Baker D, Chernajovsky Y. Cloning and expression of murine IFNb and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Therapy 1998; 5 253-263.
7. Schaefer C, Hidalgo TR, Cashion L, Petry H, Brooks A, Szymanski P et al. Gene-based delivery of interferon-beta is efficacious in a murine model of experimental allergic encephalomyelitis. J Interferon Cytokine Res 2006; 26: 449-454.
8. Jaini R, Hannaman D, Johnson JM, Bernard RM, Altuntas CZ, Delasalas MM et al. Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis. Mol Ther 2006; 14 416-422.
9. Baron U, Bujard H. Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances. Methods Enzymol 2000; 327: 401-421.
10. No D, Yao TP, Evans R. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 1996; 93: 3346-3351.
11. Pollock R, Clackson T. Dimerizer-regulated gene expression. Curr Opin Biotechnol 2002; 13: 459-467.
12. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA 1999; 96: 355-360.
13. Nordstrom JL. Antiprogestin-controllable transgene regulation in vivo. Curr Opin Biotech 2002; 13: 453-458.
14. Nordstrom JL. The anti-progestin-dependent GeneSwitch® system for regulated gene therapy. Steroids 2003; 68: 1085-1094.
15. Szymanski P, Kretschmer PJ, Bauzon M, Jin F, Qian HS, Rubanyi GM et al. Development and validation of a robust and versatile one-plasmid regulated gene expression system. Mol Ther 2007; 15: 1340-1347.
16. Petry H, Cashion L, Szymanski P, Ast O, Orme A, Gross C et al. Mx1 and IP-10: Biomarkers to measure interferon-beta activity in mice following gene-based delivery. J Interferon Cytokine Res 2006; 26: 699-705.
17. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Immunol 1996; 64: 91-100.
18. Tuohy VK, Yu M, Yin L, Mathisen PM, Johnson JM, Kawczak JA. Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J Neuroimmunol 2000; 111: 55-63.
19. Goodin DS. Treatment of multiple sclerosis with human beta interferon. Int MS J 2005; 12: 96-108.
20. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.
21. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 2000; 7: 1156-1165.
22. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006; 6: 243-273.
23. Wells DJ. Viral and non-viral methods for gene transfer into skeletal muscle. Curr Opin Drug Discov 2006; 9: 163-168.
24. Ratanamart J, Shaw JAM. Plasmid-mediated muscle-targeted gene therapy for circulating therapeutic protein replacement: A tale of the tortoise and the hare? Curr Gene Ther 2006; 6: 93-110.
25. Sitruk-Ware R, Spitz IM. Pharmacological properties of mife-pristone: toxicology and safety in animals and human studies. Contraception 2003; 68: 409-420.
26. DeBattista C, Belanoff J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trend Endocrinot Metab 2006; 17: 117-121.
27. Majumder S, Zhou LZH, Chaturvedi P, Babcock G, Aps S, Ransohoff RM. Regulation of human IP-10 gene expression in astrocytoma cells by inflammatory cytokines. J Neurosci Res 1998; 54: 169-180.
28. Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-198.
29. Buttmann M, Merzyn C, Rieckmann P. Interferon-β induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol 2004; 196: 195-203.
30. Hong J, Zang YZQ, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 2004; 152: 126-139.
31. Trollet C, Bloquel C, Scherman P, Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther 2006; 6: 561-578.
32. Brooks AR, Wang P, Wu F, Harkins RN. Inflammatory gene expression profile following electroporation enhanced delivery of plasmids to skeletal muscle (submitted for publication).
33. Yew NS, Zhao H, Prizbylska M, Wu IH, Tousignant JD, Scheule RK et al. CpG-depleted plasmid DNA vectors with enhanced safety and long-term gené expression in vivo. Mot Ther 2002; 5: 731-738.
34. Yew NS, Cheng SH. Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy. Expert Opin Drug Deliv 2004; 1: 115-125.
35. Hodges BL, Taylor KM, Joseph MF, Bourgeoios SA, Scheule RK. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004; 10: 269-278.
36. Gronevik E, von Steyern FV, Kalhovde JM, Tjelle TE, Mathiesen J. Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J Gene Med 2005; 7: 218-227.
37. Abruzzese RV, MacLaughlin FC, Smith LC, Nordstrom JL. Regulated expression of plasmid-based gene therapies. Methods Mol Med 2002; 69: 109-122.
38. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 2001; 97: 473-482.